港股异动 | 康方生物(09926)高开近3% 小摩预测AK112在美国市场销售潜力最多增加9亿美元

智通财经网11-04

智通财经APP获悉，康方生物(09926)高开近3%，截至发稿，涨2.93%，报70.2港元，成交额596.7万港元。摩根大通发布研报指出，康方生物管理层透露已非鳞状细胞癌患者纳入AK112的全球三期临床研究HARMONi-3当中，计划招募1,080名患者，以评估鳞状和非鳞状非小细胞肺癌(NSCLC)的一线(1L)患者治疗情况，除了总生存期外，无恶化生存期亦将被纳入为新的共同主要终点。该行认为，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2480317433?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-04 09:26","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2480317433","market":"hk","top_or_hot":-1,"title":"港股异动 | 康方生物(09926)高开近3% 小摩预测AK112在美国市场销售潜力最多增加9亿美元","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，康方生物(09926)高开近3%，截至发稿，涨2.93%，报70.2港元，成交额596.7万港元。摩根大通发布研报指出，康方生物管理层透露已非鳞状细胞癌患者纳入AK112的全球三期临床研究HARMONi-3当中，计划招募1,080名患者，以评估鳞状和非鳞状非小细胞肺癌(NSCLC)的一线(1L)患者治疗情况，除了总生存期外，无恶化生存期亦将被纳入为新的共同主要终点。该行认为，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1206084.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康方生物(09926)高开近3% 小摩预测AK112在美国市场销售潜力最多增加9亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康方生物(09926)高开近3% 小摩预测AK112在美国市场销售潜力最多增加9亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 09:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1206084.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康方生物(09926)高开近3%，截至发稿，涨2.93%，报70.2港元，成交额596.7万港元。摩根大通发布研报指出，康方生物管理层透露已非鳞状细胞癌患者纳入AK112的全球三期临床研究HARMONi-3当中，计划招募1,080名患者，以评估鳞状和非鳞状非小细胞肺癌(NSCLC)的一线(1L)患者治疗情况，除了总生存期外，无恶化生存期亦将被纳入为新的共同主要终点。该行认为，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1206084.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348783233.USD","symbol_name":"安联东方收入型 CI A Dis美元","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1206084.html","article_id":"2480317433","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480317433","pubTimestamp":1730683608,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，康方生物高开近3%，截至发稿，涨2.93%，报70.2港元，成交额596.7万港元。该行认为，新进展是对AK112发展潜力的又一次信心证明，考虑到约70%的NSCLC患者属于非鳞状类别，将该因素纳入AK112的海外市场预测模型后，目前预测AK112在美国市场销售潜力最多增加9亿美元，2028至2033年销售额预测亦上调3%至6%，目标价相应由68港元上调至74港元，评级“增持”。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","BK4207":"综合性银行","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK1161":"生物科技","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","BK4581":"高盛持仓","IE00BYXW3230.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"AA\" (USD) ACC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0215105999.USD":"SCHRODER ISF GLOBAL EQUITY \"A\" ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4588":"碎股","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK4550":"红杉资本持仓","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU":"陆金所","LU0971096721.USD":"富达环球金融服务 A","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU0149725797.USD":"汇丰美国股市经济规模基金","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4534":"瑞士信贷持仓","LU0238689110.USD":"贝莱德环球动力股票基金","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","BK4566":"资本集团","09926":"康方生物","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","LU0106831901.USD":"贝莱德世界金融基金A2","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC"},"translate_title":"Hong Kong stock changes Akeso Biotech (09926) opened nearly 3% higher JPMorgan predicts that AK112's sales potential in the U.S. market will increase by up to US $900 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1,"LU":0.6},"content_text":"智通财经APP获悉，康方生物(09926)高开近3%，截至发稿，涨2.93%，报70.2港元，成交额596.7万港元。摩根大通发布研报指出，康方生物管理层透露已非鳞状细胞癌患者纳入AK112的全球三期临床研究HARMONi-3当中，计划招募1,080名患者，以评估鳞状和非鳞状非小细胞肺癌(NSCLC)的一线(1L)患者治疗情况，除了总生存期外，无恶化生存期亦将被纳入为新的共同主要终点。该行认为，新进展是对AK112发展潜力的又一次信心证明，考虑到约70%的NSCLC患者属于非鳞状类别，将该因素纳入AK112的海外市场预测模型后，目前预测AK112在美国市场销售潜力最多增加9亿美元，2028至2033年销售额预测亦上调3%至6%，目标价相应由68港元上调至74港元，评级“增持”。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480317433"}